Lisa Castellano-Howard, MD
Dermatology · Tampa, FLNPI 1588631683
Payments from drug & device makers
What this record shows
UCB SA accounts for 62.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $2,674 and has fallen 87.1% since, to $345 in 2025.
Across 41 payments — averaging $86.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$2K
- Sun Pharmaceutical Industries Inc.$311
- Organogenesis Inc.$263
- Galderma Laboratories, L.p.$171
- Teva Pharmaceuticals USA, Inc.$140
- E.r. Squibb & Sons, L.L.C.$115
- plus $336 from 9 others
What the payments were for
- Travel & lodging$2,08259%
- Food & beverage$1,47541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 7 | $2,223 |
| Sun Pharmaceutical Industries Inc. | 5 | $311 |
| Organogenesis Inc. | 8 | $263 |
| Galderma Laboratories, L.p. | 2 | $171 |
| Teva Pharmaceuticals USA, Inc. | 1 | $140 |
| E.r. Squibb & Sons, L.L.C. | 1 | $115 |
| Pfizer | 4 | $81 |
| Regeneron Healthcare Solutions, Inc. | 3 | $61 |
| AbbVie | 3 | $60 |
| Kyowa Kirin, Inc. | 2 | $42 |
| Genentech USA, Inc. | 1 | $24 |
| DUSA Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $17 |
| UCB, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,557 in reported general payments places this provider in the 55th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluocinonide | 20 | $913 |
| Ketoconazole | 20 | $271 |
| Doxycycline Hyclate | 18 | $176 |
| Mupirocin | 22 | $105 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Tampa
- Seth FormanTampa$407K
- Asha ShahTampa$332K
- Nishit PatelTampa$111K
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.